HTBPL1

Product by Archer Daniels Midland

Science-backed postbiotic for metabolic health and weight management solutions.

HTBPL1 is a science-backed postbiotic derived from ADM's BPL1 strain, designed for food, beverage, and supplement manufacturers to support metabolic health and weight management.

Languages
English

Category: Food Production

Sizes and variants
Postbiotic derivative of BPL1 strain
Research Duration
9+ years
Scientific Publications
50+ microbiome-related publications
Clinical Trial Type
Randomized, double-blind, placebo-controlled
Primary Benefit
Metabolic health and BMI impact
Form Factor
Postbiotic derivative
  • Postbiotic derived from BPL1 probiotic strain
  • Clinically documented impact on metabolic health markers including BMI
  • Supported by 50+ microbiome-related publications
  • Result of 9+ years of research and development

Overview

HTBPL1 is a postbiotic ingredient derived from ADM's BPL1 probiotic strain, specifically developed for inclusion in food, beverage, and dietary supplement applications. It serves health and wellness brands by providing science-backed solutions for metabolic health and weight management. The product is the result of over nine years of research and development, including randomized, double-blind, placebo-controlled clinical trials. HTBPL1 allows manufacturers to deliver microbiome-supporting benefits in various formats where live probiotics might not be stable or suitable. It helps address consumer demand for products that impact markers of metabolic health, such as BMI, through proprietary, patent-protected science. ADM supports the integration of this ingredient with specialized technologies to enhance product development efficiency.

Application and Versatility

  • Postbiotic Derivative: The strain is a postbiotic derived from ADM's BPL1 probiotic strain, specifically designed for applications where live probiotics may not be suitable.
  • Food and Beverage Integration: The product is designed for inclusion in a wide range of food and beverage formats, such as yogurt, to meet health-conscious consumer needs.
  • Dietary Supplement Applications: Manufacturers can utilize the ingredient in dietary supplement applications to provide microbiome-supporting benefits.
  • Development Efficiency: ADM provides specialized technologies to enhance product development efficiency and improve the final consumer experience.

Health and Wellness Benefits

  • Extensive R&D: The development of the strain involved more than nine years of intensive research and development.
  • Scientific Validation: The product is supported by over 50 microbiome-related publications and human clinical trials, including randomized, double-blind, placebo-controlled studies.
  • Patent-Protected Science: The strain utilizes proprietary, patent-protected science to ensure unique functionality for health and wellness brands.

Use cases

  • Health and wellness brands incorporate HTBPL1 into dietary supplements to provide clinically validated metabolic health benefits.
  • Food manufacturers add the postbiotic to yogurt and other dairy products to appeal to health-conscious consumers seeking weight management support.
  • Beverage companies use HTBPL1 to create functional drinks that target microbiome health in formats where live probiotics are not suitable.

Specifications

Sizes and variants
Postbiotic derivative of BPL1 strain
Research Duration
9+ years
Scientific Publications
50+ microbiome-related publications
Clinical Trial Type
Randomized, double-blind, placebo-controlled
Primary Benefit
Metabolic health and BMI impact
Form Factor
Postbiotic derivative

FAQ

What is HTBPL1?

HTBPL1 is a postbiotic derived from ADM's BPL1 probiotic strain, designed for use in food, beverage, and dietary supplement applications where live probiotics might not be suitable.

Who is HTBPL1 for?

It is intended for health and wellness brands seeking science-backed solutions for metabolic health and weight management.

What scientific evidence supports HTBPL1?

It is the result of over nine years of research and development, supported by more than 50 microbiome-related publications and human clinical trials.

Added by AntSpace from public sources (adm.com).

Related

More products by Archer Daniels Midland